Gavegnano Lab Accomplishments

FDA Approved Drug

Baricitinib for the use of COVID-19, first line treatment status worldwide; greatest reduction in mortality above any standard of care.

• CID paper (first published 2020)
• NEJM ACTT2 paper
• Lancet RM RECOVERY trial (Marconi lead)

Multiple ongoing human trials

• Phase 2a study to evaluate the efficacy and safety of baricitinib for reduction of HIV in the central nervous system.
• Elucidating the role of the gut reservoir and inflammation in driving cardiovascular disease among persons living with HIV (non-interventional)
• Phase 2a study to evaluate baricitinib to reverse treatment resistant depression in people living with HIV.
• Phase 3 study REVERSE-Long COVID: A Multicenter Randomized, Placebo-Controlled Clinical Trial of Immunomodulation (With Baricitinib) for Long COVID Related Cognitive Impairment and ADRD (Alzheimer's Disease and Related Dementias)